ERElena María Rincón-López

Elena María Rincón-López

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena María Rincón-López has a total of 187 co-authors. Here are the top co-authors by number of shared publications:

  • Jesús Saavedra-Lozano

    Pediatric Infectious Diseases Department, Gregorio Marañón University Hospital, Madrid, Spain

    7 shared publications
  • David Aguilera-Alonso

    Pediatric Infectious Diseases Department, Gregorio Marañón University Hospital, Madrid, Spain

    6 shared publications
  • Teresa Hernández-Sampelayo Matos

    Hospital General Universitario Gregorio Marañón

    6 shared publications
  • María Luisa Navarro Gómez

    Department of Pediatrics, Pediatric Infectious Diseases Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

    5 shared publications
  • Carlos Grasa

    Paediatric Infectious Diseases Department Hospital Universitario La Paz (Madrid) Madrid Spain

    4 shared publications
  • Cristina Beléndez Bieler

    Department of Pediatrics. Pediatric Hematology and Oncology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    4 shared publications

Latest Publications

  • Open Access

    Azole‐Resistant Aspergillosis: An Emerging Diagnostic and Therapeutic Challenge in Paediatrics

    by Natalia Mendoza‐Palomar, Carlos Grasa Lozano, Begoña Carazo‐Gallego, Elena María Rincón‐López, Maria Pinyol‐Sarrias, Anna Creus‐Costa, Ana Méndez‐Echevarría, Alfredo Maldonado‐Barrueco, Yasmina Mozo, Diego Lozano‐Durán, et al.

    Introduction: Invasive aspergillosis (IA) represents one of the most frequent invasive fungal infections in paediatric patients with risk factors. An increase in cases of azole‐resistant IA has been reported in adult patients. The aim of this study is to present a series of 11 cases of paediatric patients with this pathology. Methods: A retrospective descriptive study including paediatric patients with probable or proven azole‐resistant IA treated between January 2019 and June 2024 in four tertiary hospitals in Spain. Results: Eleven cases are reported, all patients with risk factors for IA, mainly with haematopoietic stem cell transplantation (HCT) due to haematological malignancies and heart transplant in the early post‐transplant period. These patients represent 22% of all proven or probable paediatric IA cases ( n = 50) diagnosed in the study centres during the period. Five were previously receiving azole‐based antifungal prophylaxis. The most frequently isolated species was Aspergillus fumigatus . Despite receiving at least partially active antifungals plus adjunctive treatment therapy from diagnosis, attributable mortality was high (8/11 patients). Conclusion: Azole‐resistant IA should be suspected in paediatric patients with risk factors, especially if they show poor clinical course or have received azole prophylaxis. The performance of invasive tests, as well as species identification and resistance testing, is essential to optimise treatment. In breakthrough IA it should be considered empirical treatment with an antifungal from a different class than the one used for prophylaxis, alone or in combination.

  • Open Access

    Real-life use of isavuconazole in Spanish children and adolescents

    by Natalia Mendoza-Palomar, Silvia Simó Nebot, Laura Roig-Soria, Laura Alonso García, Clara Izquierdo Anto, Marta Taida García Ascaso, David Díaz Pérez, Carlos Grasa Lozano, Cristina Jiménez Núñez, Elena María Rincón López, et al.

    Background and Objectives: Isavuconazole (ISA) has been recently approved for the treatment of invasive aspergillosis and mucormycosis in patients aged >1 year. Prior to this approval, it was used in paediatric patients under compassionate use. The objective of this study is to describe the experience with ISA use in children. Patients and methods: A descriptive, retrospective, multicentre study conducted in nine Spanish hospitals, including patients aged ≤18 years who received ≥7 days of ISA between 2018 and 2023. Therapeutic drug monitoring (TDM) was performed with pre-dose [trough concentration (Ctrough)] levels measured according to local protocols. A therapeutic range of 2.5–5 mg/L was used for analysis. Results: A total of 107 patients (median age: 11 years, 56% male) were included. ISA was used as a treatment (95 patients), mostly as second-line therapy (64 patients, 67%), due to toxicity from previous antifungals (27 patients, 42%). Of 53 patients with proven/probable invasive fungal disease (IFD), 32 (60%) showed a favourable response and 21 (40%) died, 13 due to IFD. Twelve patients received ISA as prophylaxis and none developed breakthrough IFD. Overall, 27/107 (25%) patients experienced adverse effects, the most common being hepatotoxicity, with 10 requiring discontinuation. TDM was performed in 76/95 patients (80%), revealing 59% of Ctrough values outside the therapeutic range. Conclusions: ISA appears to be a safe and effective option for treating IFD in children, especially when first-line agents have failed or caused excessive toxicity. Although no correlation between Ctrough and clinical outcomes was observed, the significant proportion of patients with out-of-range Ctrough emphasizes the need for TDM in paediatrics.


  • Antifungal Prescribing in European Pediatric Intensive Care Units: Results of a Multinational 3-Month Weekly Point-Prevalence Survey

    by Elisavet Chorafa, Elias Iosifidis, Aisha Abdalla Alkhaaldi, Ana Arias, Benhur Sirvan Cetin, Maia De Luca, Marieke Emonts, Laura Ferreras-Antolin, Elisabetta Ghimenton-Walters, Carlos D Grasa, et al.

    Background: Critically ill pediatric patients admitted to the pediatric intensive care unit (PICU) are highly vulnerable to infections, including invasive fungal diseases and antifungal agents are frequently prescribed. Little is known about antifungal usage in PICUs across Europe. Methods: A multinational 3-month weekly point-prevalence study for measuring antifungal drug use was organized. Eigtheen PICUs (16 hospitals) in 10 countries in the European region participated. All patients hospitalized in the participating PICUs and receiving systemic antifungals were included. Information about ward demographics was collected once; weekly ward and patient data were collected prospectively for the 12-week study period and entered in REDCap database. Results: Among 18 PICUs, 8 (44%) followed prophylactic practices for targeted group of patients, 7/18 (39%) had an antifungal stewardship program and the majority (16/18, 89%) had the capacity of biomarker utilization (16/16 galactomannan, 13/16 beta-D-glucan, and 9/16 pan-fungal PCR). One hundred one courses in equal number of patients were recorded; 14 for patients aged <3 month, 87 for patients ≥3 month. Malignancy was the most common underlying condition among patients aged ≥3 month (29%) followed by surgery/trauma (25%), whereas all patients <3 month had undergone a recent surgery. Indication for antifungal prescribing was prophylaxis in 38% and treatment in 62% [empirical (57%), preemptive (13%), and targeted (30%)]. Fluconazole was the most common agent both for prophylaxis and treatment, whereas liposomal amphotericin B was the most frequent agent for targeted treatment. The majority (63%) of patients on prophylaxis were oncology or transplant patients. Common reasons for empirical and targeted treatment were persistent fever/other signs of infections in high-risk patients (61%) and Candida infections (100%), respectively. For targeted treatment, the most frequent pathogens were Candida albicans (37%) and Candida parapsilosis (32%). Conclusions: Most antifungal prescriptions across European PICUs were for treatment. Fluconazole was the most frequently prescribed antifungal. These surveillance data can guide antifungal stewardship strategies in PICUs.


  • Open Access

    Diagnostic potential of combining plasma biomarkers of tissue damage and inflammation in pediatric TB

    by Andrea López-Suárez, Mar Santos-Sebastián, Alicia Hernanz-Lobo, Elena Rincón-López, David Aguilera-Alonso, Jesús Saavedra-Lozano, María Jesús Ruiz Serrano, Ángel Hernández-Bartolomé, Luz María Medrano de Dios, José Luis Jiménez Fuentes, et al.

  • Open Access

    Pneumocystis jirovecii and SARS-CoV-2 Coinfection as Presentation of X-linked Severe Combined Immunodeficiency

    by Javier Toledano-Revenga, Cristina Zapata-Martínez, María Slöcker-Barrio, M Elena Seoane-Reula, Cristina Beléndez, Elena Rincón-López


  • Use of Monoclonal Antibodies in a Pediatric Patient With Severe Combined Immunodeficiency and Persistent SARS-CoV-2 Infection

    by Amanda Bermejo-Gómez, David Aguilera-Alonso, Elena María Rincón-López, Pilar Catalán-Alonso, Eduardo J. Bardón-Cancho, Marina García-Morín, Silvia Manrique-Rodríguez, María Luisa Navarro-Gómez

    We describe the use of monoclonal antibodies for the treatment of persistent SARS-CoV-2 infection in a pediatric patient with severe combined immunodeficiency who required urgent stem cell transplantation to cure his disease.

  • Open Access

    INTERLEUKIN 6 AS A MARKER OF SEVERE BACTERIAL INFECTION IN CHILDREN WITH SICKLE CELL DISEASE AND FEVER

    by Elena Rincon-Lopez, Maria Navarro Gómez, Teresa Hernández-Sampelayo Matos, David Aguilera-Alonso, Eva Dueñas-Moreno, Jesús Saavedra-Lozano, Begoña Santiago-Garcia, Maria Del Mar Santos, Marina García-Morin, Cristina Beléndez, et al.

    Introduction Etiological diagnosis of fever in sickle cell disease (SCD) children is often challenging. Objective: to analyze the pattern of inflammatory biomarkers in SCD febrile children and controls, in order to determine predictors of severe bacterial infection (SBI). Methods Prospective, case-control study of febrile and steady-state SCD children carried out during 3 years. Clinical characteristics and laboratory parameters, including 10 serum proinflammatory cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17a, IFN-γ and TNF-α) and comparisons among study subgroups were analyzed. Results A total of 137 patients (78 cases and 59 controls) were included in the study; 78.5% males, median age 4.1 (1.7-7.5) years. Four cases were diagnosed with SBI, 41 viral infection (VI) and 33 no proven infection (NPI). IL-6 was significantly higher in patients with SBI than in patients with VI or NPI (163 vs 0.7 vs 0.7 pg/ml, p < 0.001), and undetectable in all controls. The rest of the cytokines analyzed did not show any significant difference. The optimal cut-off value of IL-6 for the diagnosis of SBI was 125 pg/mL, with high PPV and NPV (PPV of 100% for a prevalence of 5, 10 and 15% and NPV of 98.7%, 97.3% and 95.8% for those prevalences, respectively). Conclusion We found that IL-6 (optimal cut-off value of 125 pg/ml) was a very good marker for SBI in this cohort of febrile SCD children, with high PPV and NPV. Therefore, IL-6 may be useful, alone or combined with other biomarkers, to guide the management of these patients.

  • Open Access

    INVASIVE FUNGAL DISEASE IN A PEDIATRIC HEMATOLOGY AND ONCOLOGY UNIT: A 14-YEAR PERIOD REVIEW

    by Laura Calle-Miguel, Carmen Garrido, Begoña Santiago-Garcia, Martha Patricia Moreno Santos, Henar Gonzalo Pascual, Beatriz Ponce Salas, Cristina Beléndez, Maria Navarro Gómez, Elena Rincon-Lopez

    BACKGROUND. Invasive fungal disease (IFD) is a significant cause of morbidity and mortality in immunosuppressed children. We aim to describe the epidemiology and clinical parameters of IFD in a Pediatric Hematology-Oncology Unit (PHOU) with an increasing activity during the last 14 years. METHODS. We retrospectively reviewed the medical records of children (up to 18 years old) admitted for IFD to the PHOU of a tertiary hospital in Madrid (Spain), between 2006-2019. Epidemiological, diagnostic and therapeutic parameters were compared according to the type of infection, study period (considering 3 equivalent time fractions) and outcome. RESULTS. Twenty-eight episodes of IFD occurred in 27 out of 471 children at risk (13 males, median 10 years old). Five episodes of candidemia (all in the first period) and 23 bronchopulmonary mold diseases were registered. Six (21.4%), eight (28.6%) and 14 (50%) episodes met criteria for proven, probable and possible IFD, respectively. Most episodes (71.4%) occurred in high-risk children receiving antifungal prophylaxis. Eight children required intensive care and six died during treatment. Mold infections occurred in older children (126 vs. 21 months; p=0,045), increased over time (p=0.002) and were more common in high-risk compared to low-risk children (87% vs. 0%; p=0.001). There were no differences in mortality rates between periods, types of infection or underlying conditions. CONCLUSIONS. Yeast infections decreased within the study time and mold infections were more frequent in high-risk patients. A rising activity in our PHOU and an increase in the complexity of pathologies were not followed by an increase in mortality rates.

  • Risk-score based strategy to minimize antibiotic exposure in children with sickle cell disease and fever

    by Elena María Rincón-López, María Luisa Navarro Gómez, Teresa Hernández-Sampelayo Matos, David Aguilera-Alonso, Eva Dueñas Moreno, José María Bellón Cano, Jesús Saavedra-Lozano, María del Mar Santos Sebastián, Marina García Morín, Cristina Beléndez Bieler, et al.

    Severe bacterial infections (SBI) have become less frequent in children with sickle cell disease (SCD) in the last decades. However, because of their potential risk of SBI, they usually receive empirical therapy with broad-spectrum antibiotics when they develop fever and are hospitalized in many cases. We performed a prospective study including 79 SCD patients with fever [median age 4.1 (1.7–7.5) years, 78.5% males; 17 of the episodes were diagnosed with SBI and 4 of them were confirmed] and developed a risk score for the prediction of SBI. The optimal score included CRP > 3 mg/dl, IL-6 > 125 pg/ml and hypoxemia, with an AUC of 0.91 (0.83–0.96) for the prediction of confirmed SBI and 0.86 (0.77–0.93) for possible SBI. We classified the patients in 3 groups: low, intermediate and high risk of SBI. Our risk-score-based management proposal could help to safely minimize antibiotic treatments and hospital admissions in children with SCD at low risk of SBI.


  • Open Access

    Risk-Score Based Strategy to Minimize Antibiotic Exposure in Children With Sickle Cell Disease and Fever

    by Elena Maria Rincón-López, María Luisa Navarro Gómez, Teresa Hernández-Sampelayo Matos, David Aguilera-Alonso, Eva Dueñas Moreno, José María Bellón Cano, Jesús Saavedra-Lozano, María del Mar Santos Sebastián, Marina García Morín, Cristina Beléndez Bieler, et al.

    Severe bacterial infections (SBI) have become less frequent in children with sickle cell disease (SCD) in the last decades. However, because of their potential risk of SBI, they usually receive empirical therapy with broad-spectrum antibiotics when they develop fever and are hospitalized in many cases. We performed a prospective study including 79 SCD patients with fever [median age 4.1 (1.7–7.5) years, 78.5% males; 17 of the episodes were diagnosed with SBI and 4 of them were confirmed] and developed a risk score for the prediction of SBI. The optimal score included CRP > 3 mg/dl, IL-6 > 125 pg/ml and hypoxemia, with an AUC of 0.91 (0.83–0.96) for the prediction of confirmed SBI and 0.86 (0.77–0.93) for possible SBI. We classified the patients in 3 groups: low, intermediate and high risk of SBI. Our risk-score based management proposal could help to safely minimize antibiotic treatments and hospital admissions in children with SCD at low risk of SBI.